← Back to headlines
Truist Increases Price Target for Immunovant While Maintaining Hold Rating
Truist has raised its price target for Immunovant, Inc. (IMVT) but has chosen to maintain a "Hold" rating on the stock.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
U.S. Treasury Yields Surge as Fed Official Signals Support for Rate Hike
1h ago
Kalshi Permanently Bans George Santos Over Insider Trading on State of the Union Bets
1h ago
Dell Stock Gains Investor Focus Ahead of September Earnings Report
1h ago
Sony and Warner Music Sue Anthropic Over AI Training Copyright Claims
1h ago